We identify errors associated with multiplexing that could potentially impact on 32 the accuracy of MRD analysis. We optimise a strategy combining high purity, sequence-optimised 33 oligonucleotides, dual-indexing and an error-aware demultiplexing approach to minimise errors and 34 maximise sensitivity. We present a probability-based demultiplexing pipeline, Error-Aware 35
Introduction 40
The accurate determination of minimal residual disease (MRD) during the early months of therapy in 41 acute lymphoblastic leukemia (ALL), particularly childhood ALL, is well established as a biomarker 42 for guiding therapy [1] [2] [3] [4] [5] [6] . Current methods for MRD measurement -allele-specific real-time quantitative 43 (ASO-RQ) PCR of clone-defining immunoglobin (IG)/T-cell receptor (TCR) gene rearrangements in 44 the patients' leukemia 7, 8 and flow cytometric (FC) tracking of leukemia associated 45 immunophenotypes 1, 9 -are both expensive, time consuming and suffer from technical limitations. 46 ASO-RQ PCR requires assays tailored to each individual patient and, depending on template 47 availability and primer selection has a maximal sensitivity of 1:1x10
-5 due to non-specific background 48 amplification 10 . This prevents the identification of even lower risk patients who could benefit from 49 safer protocols that further reduce treatment-related mortality. Standardisation of FC is difficult, 50 requires experienced operators (especially pediatric samples), and inter-operator variation can lead to 51 inconsistent reporting 11 . Finally, clonal architecture is dynamic. When disease relapse occurs, it can 52 involve clones that were not identified, or only viewed as minor clones, at diagnosis and therefore 53
were not tracked 12 . 54
Advances in high throughput sequencing (HTS) offer a potential solution to these problems. Highly 55 parallel HTS can be employed to sequence the rearranged VDJ (Variable, Diverse and Joining) of the 56 immunoglobulin heavy chain (IGH) genes, which encode the hypervariable CDR3 domain. Combineddemonstrated to be rapid, accurate and reproducible 22 . Continuing development of HTS technologies 66 has resulted in cheaper platforms, such as the MiSeq (Illumina) , that operate at a capacity which more 67 appropriately matches the demands of turnaround time and cost required in clinical practice [23] [24] [25] . experiments generate large datasets. Interpretation and reproducibility of these data are of crucial 76 importance in the development of a reliable clinical assay 26 . Use of these technologies in clinical 77 practice has been cautioned until they are fully validated 27 . 78
The potential for primer bias influencing MRD detection has been extensively modelled by other 79 groups 28 , so we do not address this here. The amplification strategy used for the current ASO-RQ 80 PCR assay is already clinically approved 10 and therefore provides the most practical basis for 81 translation into a HTS-MRD assay. After evaluating alternatives, we chose the MiSeq as a suitable 82 platform for delivery as it is able to sequence single read (unidirectional) libraries of sufficient length 83 (minimum 150 nucleotides) and quality to identify clones in less than 24 hours. MiSeqDx has been 84 FDA approved for diagnostic use in cystic fibrosis 29 . 85
Sequencing multiple indexed samples per run reduces costs and increases scalability; however it 86
Single-index strategy indices were HPLC purified and synthesised (Sigma-Aldrich) as per Kozarewa 118 et al. 33 We designed new dual-indices (Table 1 ) synthesised using the TruGrade process (Integrated 119 DNA Technologies) 31 . 120
Digital PCR 121
The CDR3-encoding regions of IGH genes of the cell lines described above were amplified and 122 sequenced (HTS and Sanger) to ensure clonality and purity of sequence (Supplementary figures 1 and 123 2). TaqMan assays were then designed for the unique CDR3 region. Reactions containing TaqMan 124
Gene Expression Master Mix (ABI), GE sample loading reagent (Fluidigm), TaqMan assay and 125 template DNA, were pipetted into the loading inlets of a 12.765 Digital Array (Fluidigm). The 126
BioMark IFC controller MX (Fluidigm) was used to uniformly partition the reactions into the panels. 127
Template molecules are partitioned throughout the panels with a high degree of randomness and 128 independence 34 . Absolute copy number quantification of cell line "spike-in" IGH CDR3-encoding 129 regions was performed by dPCR, using the BioMark Real-Time PCR System (Fluidigm). For each 130 12.765 dPCR array template DNA was analysed in triplicate. 131 mix with 5-10% PhiX (to offset low early cycle sequence complexity) was loaded onto the MiSeq 145 following the Illumina protocol "Preparing Libraries for Sequencing on the MiSeq" (Illumina Inc., 146
San Diego, CA). We used a single-end read from J to V to ensure optimal quality over the CDR3-147 encoding region. Indexing reads were performed to identify the 8 base pair (bp) index sequences 148 (single or dual-indexed). Sequencing runs performed in this study are listed in Table 2 . The pre-149 processed (i.e. multiplexed bcl) data files discussed are available in controlled access format in the 150
European Genome-phenome archive (EGAS00001001303). Custom bioinformatics pipelines were 151 used to identify, cluster and annotate sequencing reads. 152
For evaluation of our workflow in clinical practice we used 5 randomly chosen real patient samples 153
(MRD quantified for patient stratification by ASO RQ-PCR as gold standard). HTS workflows with 154
and without the technical safeguards described in the paper, where then followed. Input sample was 155 100 000 cell equivalent DNA. The HTS preparations also included separately indexed diagnostic 156 sample of each patient at a one in ten dilution to further test the versatility of the workflow. MRDexperiment, we also instructed the demultiplexing program to search for the remaining indices that 169 had been synthesised, but were not included in the experiment. 170
In a typical experiment (A7BK7, 
Quality scores of misassigned reads 182
To assess the extent of sequencing error we generated quality scores for the misassigned reads and 183 their associated index reads using FASTQC -www.bioinformatics.babraham.ac.uk/projects/fastqc/ -184 (representative examples from run A7ELC on Table 2 are shown in Figure 3 ). We discovered that the 185 quality of misassigned sample and index reads ( Figure 3D , F) is inferior to that of reads assigned to 186 real samples ( Figure 3A , C) and deteriorates with sequence length, resulting in poor mean quality 187 scores ( Figure 3E ). For the index reads, average Phred quality score for correctly assigned reads was 188 32.5 (range 30.4 -35.2) ( Figure 3C ) compared to 19.3 (range 18.4 -22.1) for misassigned index 189 reads ( Figure 3F ). This gives a mean difference of 13.3 which was highly significant with p < 0.00001 190 (95% CI 11.5 -15.2). These results indicate that misassignment stems at least in part from poor 191 quality index reads and read quality filters are required to ensure the most accurate demultiplexing 192
strategy. 193

Redesigned oligonucleotide indices 195
Misassignment may also result from oligonucleotide cross-contamination during synthesis, as 196 previously shown by Quail et al 31 . We designed a new set of 8-mer oligonucleotide indices with high 197
Hamming distance to optimise maximal sequence difference, homopolymer length and GC/AT 198 balance 35, 36 . These were then synthesised using the high purity TruGrade process which reduces the 199 risk of factory cross-contamination of oligonucleotide stocks 31 . We adopted a dual-indexing approach 200 previously shown to improve accurate demultiplexing 30 , increasing total index nucleotides to 16 bp 201
(an 8 bp index on either end of the amplicon). Twenty-four i7 and sixteen i5 indices were designed 202 (Table 1) . In order to monitor frameshift errors, some oligonucleotides were designed with sequences 203 which maintained a high Hamming distance compared to other sequences, but which were shifted by 204 a single base position (Supplementary table 4). Initially we synthesised only indices i7 1-12 and i5 1-205
206
A sequencing run was performed using this new indexing strategy (A7ELC, Table 2 ). Thirty-one 207 samples were multiplexed and sequenced. All index combinations of the indices i7 1-12 and i5 1-8 208
were entered on the sample sheet, giving a total comprised of 31 double-indexed samples, 65 index 209 combinations synthesised but not used in the experiment, and 288 index combinations where 210 oligonucleotides were not synthesised at all. 211
We found that for the majority of combinations, the new strategy eliminated the assignment of reads 212
to indices not present in the sequencing mix (Table 3 and Supplementary table 5) . This was the case 213 regardless of whether the sequences were synthesised or not, suggesting that factory oligonucleotide 214 cross-contamination is effectively eliminated by TruGrade synthesis. However, significant 215 misassignment due to amplification or sequencing error remained a problem. As anticipated, we 216 detected significant misassignment to indices where a frameshift had been introduced in the index. 217
For example, even though the two index sequences have a high Hamming distance, frameshift 218 between index i7_05 AACTCCGC and index i7_22 ACTCCGCA ( Our results show that the use of dual indices designed to maximise Hamming difference and minimise 223 frameshift error reduces the risk of misassignment of samples in multiplexed MRD. However, it is 224 apparent that even without frameshift error, up to 0.5% of reads are still assigned to non-existent 225 index combinations for dual index reads (e.g. Table 3 ; i7_04/i5_06). This suggests similar errors must 226 be present but hidden in the undetectable (mis)-assignment of reads to real indices using dual or single 227 index strategies. This could clearly pose a concern for accurate MRD assessment. 228
MiSeq on-board demultiplexing software 229
On-board MiSeq Reporter software automatically demultiplexes MiSeq output from sequencing runs 230 and converts binary base call (bcl) files to human readable text (fastq) files for each index on the 231 sample sheet entered for the run. Clusters are assigned to a sample when the index sequence matches 232 exactly but also permit assignment with a single mismatch per index read. We modified the process to 233 assign only sample names to reads bearing a perfectly matched (i.e. 0 bp mismatch) index by 234 demultiplexing raw sequencing output data using Illumina Consensus Assessment of Sequence and 235
Variance (CASAVA) software version 1.8.2 (Illumina Inc., San Diego, CA) or bcl2fastq conversion 236 software version 18.4 (Illumina Inc., San Diego, CA), allowing for no mismatches in the index 237 sequence. The reanalysed data from run A7ELC is shown in Table 4 (and Supplementary table 7) . As 238 expected, there was a reduction in the misassigned reads (compare with Table 3 ), but also an 239 unacceptable reduction in the assigned reads, with a correspondingly large increase in the 240 undetermined bin. We noted that the quality statistics from the reads which remained misassigned 241 were generally poor with % Q30 lower for misassigned sequence reads. We therefore filtered the 242 fastq files to remove any reads with % Q30 < 70 %, < 80 % and < 90 % (Supplementary table 8) . As 243 expected we lost a greater proportion of reads from the misassigned group than from the correctly 244 assigned reads but the misassigned reads were still present and a large number of reads had been 245 discarded -potentially impacting on sensitivity. We concluded that current demultiplexing strategiesare not stringent enough for very high sensitivity applications, and do not take account of the quality 247 of the index read. 248
Use of unique index combinations 249
To further reduce the potential "hidden" misassignment, in the following run, A7FDO, we used only 250 unique combinations of group 1 indices (Supplementary table 6). We sequenced 8 samples, >1.5 251 million reads per sample, output data was demultiplexed using MiSeq on-board demultiplexer and 252 through CASAVA allowing for no mismatches in index reads, reducing overall misassignment from 253 0.2% to 0.05% (Supplementary tables 9 and 10). This shows that for MRD measurement where a 254 high degree of accuracy (minimising misassignment) is required only dual unique indices should be 255
used. 256
Demultiplexing based on quality of index reads -Error Aware Demultiplexer 257
In view of the significant misassignment using the MiSeq on-board demultiplexer, the unacceptable 258 loss of potentially informative sequences when increasing stringency to allow no mismatches, poor 259 quality statistics of misassigned index reads, we developed our own demultiplexing pipeline. "Error-260
Aware Demultiplexer" (EAD) utilises base call quality scores of index reads produced during 261
Illumina sequencing (open source available at: https://github.com/edm1/error-aware-demultiplexer). 262
The pipeline incorporates Phred scores to probabilistically match read indices to the sample identities 263 during demultiplexing. Index similarity is assessed with the same algorithm used in the Illumina pair-264 end assembler PANDAseq 37 . The pipeline calculates the probability that the true index and the index 265 read represent the same underlying sequence. For example, if two bases match and the quality of 266 those bases are high then we have good evidence that they represent the same base. Probabilities are 267 calculated for each base and multiplied together to get the probability that the two reads represent the 268 same sequence. This results in up to an 80% reduction in misassignment compared to other 269 approaches and importantly, with minimal subsequent loss of sequence reads (Table 5) . 270
Reducing run-to-run carryover 273
Template molecules may remain in the MiSeq fluidics system, even after a standard wash program, 274 and can be washed onto the flow cell in subsequent runs. MiSeq instruments maintained according to 275 standard Illumina recommendations typically have sample carryover rates of 0.1%. If the same 276
indexing strategy is applied in a subsequent run, a 0.1% carryover rate could potentially cause errors 277 in clinical interpretation of MRD. We added two non-human samples to the sequencing pool (A7ELC, 278 Table 2 ) and then performed a sequencing run (A7FDO, Table 2 ) with the same indices but different 279 samples 3 weeks later and after a further 2 different runs on the MiSeq (and therefore three standard 280 washes). Carryover was detected at a rate of 0.002%. Performing the wash recipe recommended by 281
Illumina for highly sensitive applications "Technical support: Reducing Run-to-Run Carryover on the 282
MiSeq Using Dilute Sodium Hypochlorite Solution" (Illumina Inc., San Diego, CA), completely 283 eradicated the carryover (data not shown). We observed that this wash recipe can sometimes cause 284 lower cluster densities, presumably related to small amounts of sodium hypochlorite washed onto the 285 flow cell. 286
Accurate quantification using a dPCR calculated reference "spike-in" -evidence for one in a 287 million cells detection sensitivity 288 HTS-MRD is theoretically limited by the number of cells input. To accurately quantify sensitivity, we 289 performed a "spike-in" experiment. While other groups have used plasmids or synthetic templates 18, 290 28 , we used a pre-determined quantity of reference IGH DNA target derived from B-cell leukemia 291 lines with unique IGH clonotypes extracted, prepared and accurately quantified using dPCR (data not 292 shown). Dilutions ranging from 1x10 -4 to 1x10 -6 were created by adding known quantities (1, 10 and 293 100 copies) of SUPB15, TOM-1, and REH IGH sequences into one million cell equivalents of pooled 294 donor lymphocyte DNA. We then amplified the DNA of all one million cells and sequenced the 295 products using the HTS strategy described above. The sequencing run (ABG7Y, Table 2) was 296 demultiplexed using EAD resulting in over 2.5 million reads per sample. We found using our 297 workflow HTS-MRD achieved linear amplification, with R 2 > 0.9998, good reproducibility ( Figure 4 ) 298 and the ability to detect the spike-in cell line IGH target down to one copy in a million normal cell 299 equivalents. 300
Application to clinical MRD samples 301
To compare the effectiveness of our workflow with a standard HTS approach, we prepared libraries 302 from five clinical samples previously scored for MRD by the gold standard ASO-PCR assay and 303 classified into risk categories based on a 0.01% threshold. Each sample was indexed and sequenced 304 together with 10 -1 dilutions of its own diagnostic sample tagged with a different index. 305
Demultiplexing and pre-processing errors in standard HTS workflows results in false positive risk 306 classification due to the misassignment of diagnostic sample to patient MRD ( Figure 5A ). In the clinic 307 this would lead to overtreatment of patients. The scenario was then repeated using the improved 308 workflow with EAD. The samples were now all correctly classified ( Figure 5B ). This experiment 309
demonstrates the potential clinical consequences of misclassification, and the power of an improved 310 workflow to prevent this occurring even with a one in ten dilution of diagnostic sample present in the 311
material. 312
Discussion 313
Several groups have demonstrated that HTS of the rearranged IGH gene is a potentially sensitive 314 method for MRD detection in patients with ALL 15, 16, 18, 38 . However, adoption of new approaches in 315 clinical laboratories requires careful evaluation of all potential sources of error and the development 316 of strategies to ensure the highest accuracy 27 . 317
Several important sources of potential error impact on workflow choice for HTS-MRD. Differential 318 hybridisation kinetics of oligonucleotide primers can introduce significant biases that alter the 319 composition of sequence libraries prepared by multiplex PCR 28 . However, for EuroMRD approved 320 centres 10 , the accepted clinical diagnostic assay for MRD is PCR based using consensus primers and it 321 therefore seemed reasonable to adopt the same primer sets as the basis for the proposed HTS-MRD 322 test. The Illumina MiSeq is subject to characteristic base-calling errors, but these are significantly 323 lower than current competing systems. Kennedy et al. 39 describe a ligation and capture based assay 324 which overcome HTS errors, but the method is not suitable for introducing molecular indices into the 325 specific locus for IG/TCR genes. Current techniques used for sensitive HTS-MRD are all amplicon-326 based approaches. 327
Multiplexing of indexed samples means that HTS-MRD could be an economical clinical assay. 328
However, our analysis identified low, but clearly detectable and clinically relevant levels of sample 329 misassignment using the standard MiSeq demultiplexing approach. We therefore developed a strategy 330 that reduces misassignment to the absolute minimum while maintaining maximal sensitivity. 331
We adopted TruGrade-synthesised oligonucleotide primers designed with a high Hamming distance 332 and screened to avoid frameshift error. Quail et al. reported contamination rates for purification by 333 HPLC or PAGE purification of 0.56% and 0.34%, however with TruGrade this reduced to just 334 0.03% 31 . Also, for high sensitivity applications, unique combination dual-indexing, which identifies 335 the sample origin of each sequence twice, independently, during demultiplexing, is superior to single-336 index multiplex sequencing 30 . 337
Although misassigned reads are broadly of low quality, filtering based on read quality alone is an 338 inefficient method for improving accuracy. A better method is to filter on index read quality, so we 339 developed a custom demultiplexing pipeline (EAD) that uses a probabilistic approach to remove 340 unreliable index reads while optimising retention of informative sequences. EAD out-performs 341 standard demultiplexing software, including the on-board MiSeq demultiplexer, producing high 342 quality data, with up to 80% reduction in read misassignment. Despite reduced tolerance for 343 inaccurate index reads, EAD achieves up to 10% more allocated reads (Table 5 ) than other 344 demultiplexing methods. EAD has potential application in any assay requiring highly accurate 345 demultiplexing (e.g. pathogen detection and single cell applications). We also confirmed run-to-run 346 carryover in the MiSeq fluidic pathway and demonstrated that it is essential to perform high-347 stringency post-run washes of the MiSeq to avoid the risk of contamination. Together, our workflow 348 reduces misassignment to less than 0.05% with no loss of potentially usable data, resulting in highappropriate quality control measures could provide some safeguards. Seitz et al.
40
, for example, 352 describe a novel method to prevent carry-over contaminations during similar two-step PCR protocols. 353
It will also be good practice that no diagnostic sample should be sequenced together with its follow-354
chance in B cells was 0.1% and 0.72% at 1 cell in 1 00 000 and 1 000 000 resolution respectively 16 . 360
Next, the spike-in (cell lines, synthetic templates or plasmids) used for quantification (as in all current 361 IGH HTS-MRD assays) will potentially all have the same clonal IGH sequence in each sample on the 362 same run, risking inaccurate quantification with consequent potential for misclassification. 363
Furthermore, simple human error in sample processing could result in misdiagnosis, or even where 364 detected, the cost of a repeat run. We clearly demonstrate that a 10 -1 diluted diagnostic sample can 365 result in misclassification with the standard multiplexing approach, with the likelihood presumably 366 diminishing with clone concentration. In the clinical setting, cost-effective diagnostic sequencing will 367 depend on a high degree of multiplexing with optimal use of sequencing space on cheaper, higher 368 capacity sequencers. In this scenario, cross-checking and excluding potentially contaminating highly 369 expressed clones before sequencing would be inconvenient and reduce efficiency. It is therefore 370 notable that our optimised approach with EAD reduces misassignment errors from all these scenarios 371 and allows correct classification even with a 10% diagnostic sample present. 372
We have also introduced highly accurate and biologically relevant sequencing reference controls for 373 HTS-MRD. Using dPCR, we absolutely quantified the number of molecules of biologically relevantten fold compared to the current ASO-RQ MRD approach. A major advantage of such sensitivity, 378 combined with confident sample assignment in multiplexing would be to allow application to 379 peripheral blood rather than BM, with obvious advantages for patients (especially children), as well as 380 potentially giving a more representative picture of MRD [41] [42] [43] [44] [45] [46] . 381
The improvements described represent a step towards the rigorous validation required to produce a 382 robust clinical HTS-MRD assay. Large prospective head-to-head comparison with current methods 383 are needed to prove if the increased sensitivity and broader view of IG repertoire that HTS can 384 achieve can replace the current burdensome and expensive techniques. We also propose EAD as a 385 flexible method applicable beyond MRD detection to any multiplexing approaches where high 386 accuracy of assignment is paramount. 387
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